Last reviewed · How we verify
Proton pump inhibitor
Proton pump inhibitors block the hydrogen/potassium ATPase enzyme in gastric parietal cells, reducing gastric acid secretion.
Proton pump inhibitors block the hydrogen/potassium ATPase enzyme in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Proton pump inhibitor |
|---|---|
| Also known as | pantoprazole 40mg, PPI, Omeprazole (Prilosec), Lansoprazole, Taquidine,Lansoprazole |
| Sponsor | AVM Biotechnology Inc |
| Drug class | Proton pump inhibitor |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
PPIs irreversibly inhibit the proton pump (H+/K+-ATPase), the final step in gastric acid production. This dramatically reduces intragastric pH and acid-related damage to the esophagus, stomach, and duodenum. They are used to treat and prevent acid reflux, ulcers, and related conditions.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Hypomagnesemia (with long-term use)
- Vitamin B12 deficiency (with long-term use)
Key clinical trials
- Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD (PHASE2)
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial. (NA)
- OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers (PHASE4)
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction (PHASE4)
- Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |